Literature DB >> 10368209

A KATP-channel opener as a potential treatment modality for erectile dysfunction.

D G Moon1, H S Byun, J J Kim.   

Abstract

OBJECTIVES: To assess the effects of pinacidil (a KATP-channel opener) for the treatment of penile erectile dysfunction and to examine the role of the K+-channel in cavernosal smooth muscle contractility.
MATERIALS AND METHODS: Using a feline model, the magnitude of penile erection caused by pinacidil was compared with that caused by erectogenic drugs, e.g. acetylcholine, prostaglandin E1 (PGE1) and L-arginine. The effects of K+-channel blockers (4-aminopyridine, glibenclamide and tetraethylammonium) and pinacidil on penile erections induced by the drugs were investigated.
RESULTS: The intra-arterial injection of pinacidil caused a dose-dependent increase in intracavernosal pressure (ICP) and the increase in ICP induced by pinacidil with acetylcholine, PGE1 or L-arginine was more pronounced than with the compounds alone. Furthermore, pinacidil (1 mmol/L) effectively reversed the inhibitory effects of the K+-channel blockers on the cavernosal relaxation induced by acetylcholine, PGE1 or L-arginine (P<0.01). Notably, pinacidil induced cavernosal relaxation after injecting the drugs even in cases refractory to higher concentrations (0.1 mol/L) of the drugs (n=11, P<0.01).
CONCLUSIONS: These results suggest that pinacidil is effective in relaxing feline erectile tissue in vivo, probably via increased K+ permeability and subsequent hyperpolarization. Further comparative studies with erectogenic compounds on human erectile tissue and clinical testing are required to determine whether K+-channel openers can be used in the diagnosis and treatment of erectile dysfunction. However, pinacidil seems promising as an intracavernosal agent combined with PGE1 to produce synergistic effects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10368209     DOI: 10.1046/j.1464-410x.1999.00029.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  4 in total

1.  The sGC activator BAY 60-2770 has potent erectile activity in the rat.

Authors:  George F Lasker; Edward A Pankey; Terrence J Frink; Jonathan R Zeitzer; Korey A Walter; Philip J Kadowitz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-12       Impact factor: 4.733

2.  NS11021, a novel opener of large-conductance Ca(2+)-activated K(+) channels, enhances erectile responses in rats.

Authors:  A Kun; V V Matchkov; E Stankevicius; A Nardi; A D Hughes; H J Kirkeby; J Demnitz; U Simonsen
Journal:  Br J Pharmacol       Date:  2009-10-20       Impact factor: 8.739

3.  Neuronal Voltage Gated Potassium Channels May Modulate Nitric Oxide Synthesis in Corpus Cavernosum.

Authors:  Amira M Senbel; Heba M Abd Elmoneim; Fouad M Sharabi; Mahmoud M Mohy El-Din
Journal:  Front Pharmacol       Date:  2017-05-26       Impact factor: 5.810

Review 4.  Oral and injectable medications for the treatment of erectile dysfunction.

Authors:  C C Carson
Journal:  Curr Urol Rep       Date:  2000-12       Impact factor: 2.862

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.